PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480779
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1480779
Vasculitis Treatment
Global Vasculitis Treatment Market to Reach $662.4 Million by 2030
The global market for Vasculitis Treatment estimated at US$487.6 Million in the year 2023, is expected to reach US$662.4 Million by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Biologics Drug Class, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$360.6 Million by the end of the analysis period. Growth in the Corticosteroids Drug Class segment is estimated at 3.2% CAGR for the next 7-year period.
The U.S. Market is Estimated at $146 Million, While China is Forecast to Grow at 4.1% CAGR
The Vasculitis Treatment market in the U.S. is estimated at US$146 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$115.2 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 3.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.
Introducing Our Exciting New Report Features for 2024
Full access to influencer engagement stats
Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants' privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
Complimentary report updates for one year
Competitor coverage with global market shares of major players
Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
Select Competitors (Total 23 Featured) -
- AB Science SA
- Ablynx NV
- Acorda Therapeutics, Inc.
- Antares Pharma, Inc.
- Astellas Pharma, Inc.
- AstraZeneca PLC
- Baxter International, Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Can-Fite BioPharma Ltd.
- Celgene Corporation
- Celltrion Healthcare Co., Ltd.
- Coherus BioSciences
- Daiichi Sankyo Co., Ltd.
- Eisai Co., Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Hospira, Inc.
- Idera Pharmaceuticals, Inc.
- Immunomedics, Inc.
- Incyte Corporation
- Lexicon Pharmaceuticals, Inc.
- MedImmune LLC
- Merck & Co., Inc.
- Morphotek, Inc.
- Novartis AG
- Novo Nordisk A/S
- Regeneron Pharmaceuticals, Inc.
- Sandoz International GmbH
- Sanofi SA
- Takeda Pharmaceutical Co., Ltd.
- UCB SA
- Vertex Pharmaceuticals Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Vasculitis Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Vasculitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 2: World Historic Review for Vasculitis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 3: World 16-Year Perspective for Vasculitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 5: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 6: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 8: World Historic Review for Immunosuppressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 9: World 16-Year Perspective for Immunosuppressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 11: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 12: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 13: World Vasculitis Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
- UNITED STATES
- Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 14: USA Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 15: USA Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 16: USA 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- CANADA
- TABLE 17: Canada Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 18: Canada Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 19: Canada 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- JAPAN
- Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 20: Japan Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 21: Japan Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 22: Japan 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- CHINA
- Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 23: China Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 24: China Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 25: China 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- EUROPE
- Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 26: Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Vasculitis Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Vasculitis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 29: Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- FRANCE
- Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 32: France Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 33: France Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 34: France 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- GERMANY
- Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 35: Germany Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 36: Germany Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 37: Germany 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- ITALY
- TABLE 38: Italy Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 39: Italy Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 40: Italy 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- UNITED KINGDOM
- Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 41: UK Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 42: UK Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 43: UK 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- REST OF EUROPE
- TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: Rest of Europe Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 46: Rest of Europe 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- ASIA-PACIFIC
- Vasculitis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 48: Asia-Pacific Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 49: Asia-Pacific 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
- REST OF WORLD
- TABLE 50: Rest of World Recent Past, Current & Future Analysis for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 51: Rest of World Historic Review for Vasculitis Treatment by Drug Class - Corticosteroids, Immunosuppressants and Biologics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 52: Rest of World 16-Year Perspective for Vasculitis Treatment by Drug Class - Percentage Breakdown of Value Sales for Corticosteroids, Immunosuppressants and Biologics for the Years 2014, 2024 & 2030
IV. COMPETITION
